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Background/aim: MicroRNAs (miRNAs) are known up-to-date candidate biomarkers for several diseases. In addition, obtaining
miRNA from different body fluids such as serum, plasma, saliva, and urine is relatively easy to handle. Herein we aimed to detect
miRNAs as biomarkers for early stage prostate cancer (PC). For this purpose, we used urine and serum samples to detect any significant
differences in miRNA profiles between patients and healthy controls.
Materials and methods: Total ribonucleic acid (RNA) in urine and serum samples were isolated from eight untreated PC patients, thirty
healthy individuals were screened for miRNA profile, and candidate miRNAs were validated. Whole urinary and serum miRNA profile
was analyzed using Affymetrix GeneChip miRNA 4.0 Arrays. Candidate miRNAs were investigated by stem-loop reverse transcriptionpolymerase chain reaction.
Results: When we analyzed the urinary samples of PC patients, 49 miRNAs were detected to be upregulated and 14 miRNAs were found
to be downregulated when compared with healthy controls. According to the serum samples, 19 miRNAs were found to be upregulated,
and 21 miRNAs were found to be downregulated when compared with healthy individuals as well. Interestingly, we detected only four
overlapping miRNAs (MIR320A, MIR4535, MIR4706, MIR6750) that commonly increase or decrease in both serum and urine samples.
Among them, MIR320A was found to be downregulated, and MIR4535, MIR4706, and MIR6750 were found to be upregulated for urine
samples. However, only MIR6750 was upregulated and the other three miRNAs were downregulated for serum samples.
Conclusion: Notably, the expression profile of MIR320A was significantly altered in urine specimens of prostate cancer patients. We
considered that MIR320A has been evaluated as a valuable biomarker that can be used in the early diagnosis of PC.
Key words: Prostate cancer, biomarker, microarray, miRNA profiling

1. Introduction
Prostate cancer (PC) is the second common cancer in
developed countries, and also the most frequent cause of
cancer-related mortality in men after lung cancer [1]. The
incidence and prevalence of PC varies between different
geographical regions, e.g., the most common in North
America and less common in South Asia [2].
The main diagnostic criteria in PC are digital rectal
examination (DRE), serum prostate-specific antigen
(PSA) level, and transrectal ultrasound-guided biopsy,
respectively. The PSA is exclusively expressed in prostate
tissue, yet it is not specific for diagnosis [3]. Increased levels
may be associated with numerous clinical conditions such
as benign prostate hyperplasia (BPH), prostatitis, other

infections, trauma, and urinary retention. [4,5]. Currently,
the measurement of PSA is the most common PC indicator
[6,7]. However, PC was detected in only 25% of individuals
who underwent prostate biopsy based on elevated PSA
level (>4.0 ng/mL) [4,5]. In addition, the PSA test has
some limitations [4] causing a low positive predictive
value (approximately 25%–40%) [4,8]. The role of PSA in
prostate cancer has become increasingly controversial [9].
False-negative results and low specificity have limited the
application of the clinical use as a diagnostic parameter.
miRNAs are uncoded RNAs that transcribe gene
expression with the average length from 19 to 25 nucleotides
[10,11]. Each miRNA binds to the 3’ untranslated region
(UTR) of its target mRNA [12], and inhibits the gene
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expression of multiple targets by binding to more than one
region of mRNA’s [13].
Recent studies have shown that miRNAs play
important roles in many critical biological processes,
including development, proliferation, differentiation,
apoptosis, tumor formation, signal transduction, organ
development, and hematopoietic lineage differentiation
[14]. In the literature, there are several studies evaluating
different miRNAs as biomarker for early diagnosis [15–
18]. Although PSA levels are principally used for diagnosis
in PC, despite some controversial cases, additional
biomarkers are required to make a definitive diagnosis.
For this purpose, the present study demonstrated PCrelated miRNAs such as MIR141, MIR21, MIR200B,
MIR221, and MIR375. Particularly, MIR375, identified as
a urine-associated miRNA, is directly related to stage two
PC [19]. Importantly, a recent metaanalysis demonstrated
10 upregulated and 14 downregulated miRNAs that may
discriminate PC from BPH/normal control tissues [20].
miRNAs have been suggested as a novel biomarker in
cancer due to their presence in different body fluids such
as serum, plasma, saliva, and urine [21]. They may also be
used in the early diagnosis of PC [22]. As urine is one of
the most easily accessible biofluids in primary care clinics,
a urine-based new biomarker test may help to clarify PC
diagnosis. Studies show that miRNAs are a more sensitive
marker than PSA level for PC [19]. Furthermore, serum
and urinary miRNA expressions, together, may define the
diagnosis criteria for PC patients.
Understanding which miRNAs are present in urine
and serum samples when comparing controls and patients
may offer a novel insight into the early diagnosis of PC.
The aim of this study is to determine a possible biomarker
of miRNAs in serum and urine samples of PC patients
using microarray expression analysis. Selected candidate
miRNAs were investigated and validated in detail for each
sample by stem-loop qRT-PCR.
2. Materials and methods
2.1. Ethical approval
This study was conducted after receiving approval from
the Local Human Ethics Committee (approval number:
16926-22/30) from Bezmialem Vakıf University. All
protocols conformed to the ethical guidelines of the
Helsinki Declaration and written informed consent was
obtained from all subjects.
2.2. Donor recruitment
Eight patients with newly diagnosed untreated prostate
cancer (mean age, 62 years; range, 49–72 years) who were
referred from the Department of Urology were enrolled
in this study. The clinical findings of the patients are listed
in Table 1. Thirty healthy individuals (mean age, 35 years;
range, 20–73 years) who did not have either suspected

Table 1. Gleason grading system and PSA levels for patients who
have untreated prostate cancer (Gleason score; >7: high grade,
7: intermediate grade, <7: low grade). PSA: prostate-specific
antigen.
Patient

Age

Serum PSA
level (ng/mL)

Gleason score

#1

52

40

6 (3+3)

#2

49

6.39

6 (3+3)

#3

60

36

9 (5+4)

#4

67

7.6

7 (4+3)

#5

72

3.3

6 (3+3)

#6

65

22.3

7 (3+4)

#7

70

15.11

9 (4+5)

#8

61

30

7 (4+3)

cancer or any metabolic diseases were used as a control
group. Urine samples were collected and used immediately
to maintain freshness for further experiments. Blood
samples were collected using EDTA-coated tubes
(Vacuette, Grenier Bio-One, Austria). Serum samples were
separated by centrifugation at 1100 g for 10 min and stored
at –80 °C until use.
For total RNA isolation from urine samples, freshly
collected 50 mL of urine samples were centrifuged at
1210 × g for 20 min. The pellet was dissolved in 5 mL
of 1X PBS (Phosphate Buffer Solution-Thermo Fisher
Scientific, MA, USA) (pH 7.4) and continued through
lysis phase. Total RNA isolation was performed according
to the manufacturer’s protocol using the commercial kit
(Urine Total RNA Purification Maxi Kit, Norgen, Ontario,
Canada).
2.3. Total RNA isolation from serum samples
Serum samples were incubated on ice for a complete thaw
process. Immediately, triazole reagent (1:1 ratio) (Thermo
Fisher Scientific, MA, USA) and nuclease-free glycogen
(1 μg/mL) (Thermo Fisher Scientific, MA, USA) were
added, respectively. They were then incubated at room
temperature for 10 min. Afterward, 200 μL of chloroform
(Merck Millipore, Darmstadt, Germany) was added and
the samples were incubated for 15 min. Next, they were
centrifuged at 12,000 × g for 15 min at 4 °C. Upper aqueous
phase was transferred, and 1.2 mL of isopropanol (Merck
Millipore, Darmstadt, Germany) was added to the samples.
After that, the samples were vortexed and then incubated
for 10 min at room temperature. They were centrifuged
at 12,000 × g for 8 min. The supernatants were aspirated
carefully. One milliliter of 75% ethanol was added and the
samples werecentrifuged at 7500 × g for 5 min at room
temperature. The supernatant was carefully removed,
and the tubes were dried out at room temperature. Each
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pellet was resuspended with 20 μL of nuclease-free water
(AppliChem, Gatersleben, Germany) and stored at –80 °C
for further evaluation.
2.4. microRNA expression array
Stored RNA samples were incubated on ice for a complete
thaw process. The quantitative analysis of RNA was
conducted by measuring optical density at 260 nm and 280
nm using a Multiskan GO (Thermo Fisher Scientific MA,
USA) for microarray expression analysis. Between 100 and
300 ng of total RNA samples from the urine and serum
control and patient groups were pooled. GeneChip® miRNA
4.0 Array-Affymetrix (Affymetrix, Santa Clara, California,
US, catalog number 902411) microarray analysis was
performed to identify miRNAs that were significantly
differentially expressed. All microarray experiments were
performed at Ayka Laboratories (Ayka Medikal, Ankara,
Turkey). Identification of differentially expressed miRNAs
at each stage was achieved by using linear regression and
hierarchical clustering analysis with the Transcriptome
Analysis Console software from Affymetrix. The filter
settings were as follows: “Transcription Cluster ID”:
contains hsa-miR does not contain mmu-miR, “Fold
change”: +5 and −5, “False discovered rate (FDR)”: >2.0 or
<0.5 “Adjusted P-value threshold”: 0.05.
2.5. Stem-loop RT-PCR
A total of 76 samples’ (eight patients and 30 control samples
of urine and serum) reverse transcription of 500 ng total
RNA was performed using miScript II RT Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
protocol. The obtained cDNAs were stored at –20 °C
for further evaluation. Real-time PCR for miRNAs was
performed on a CFX-connect Real-Time PCR Instrument
(Biorad, CA, USA) using miScript SYBR Green PCR Kit
and miScript Primer Assay (cat no: MS00014707 and
MS00046543) both from Qiagen (Hilden, Germany)
according to the manufacturer’s instructions. As an
endogenous reference control, RNU6-2 was used [23].
The primers were as follows: hsa-miR-6750-5p:
5’CAGGGAACAGCUGGGUGAGCUGCU,
hsa-miR320a: 5’AAAAGCUGGGUUGAGAGGGCGA. Relative
miRNA expression levels were calculated using the 2-ΔΔ CT
method.
2.6. Statistical analysis
The false discovery rate (FDR) was set to <0.05 and the
minimum fold change (FC) was set to >2.0 or <0.5 for
microarray analysis. For the RT-PCR data, statistical
analysis was performed using Graph Pad (Prism 7.0,
GraphPad Software, Inc., CA, USA). The data were
compared using the Mann–Whitney U test and Sidak’s
multiple comparisons test. A p-value of <0.05 was
considered to be statistically significant.

1766

3. Results
The yield of total RNA from serum and urine specimens
was determined, and it showed significant differences
among samples of the patients and the healthy control
groups. The overall medians of urine and serum samples
were 46.5 ng/µL and 483.9 ng/µL, respectively.
To identify miRNAs differentially upregulated and/or
downregulated in PC patients, miRNA microarrays were
used to determine the total expression profile. Patients’
and healthy controls’ urine and serum samples were
pooled into four independent groups (group 1: patients
with serum sample, group 2: patients with urine sample,
group 3: healthy controls with serum sample, group 4:
healthy controls with urine sample) and were profiled
on Affymetrix GeneChip miRNA 4.0 Arrays. Affymetrix
GeneChip miRNA 4.0 Array covers of all the 2.578 mature
human miRNAs available in miRBase version 20 (June 24,
2013) were used to profile miRNA expressions [24].
The miRNA QC tool was used to assess the quality of
the array data and the principal component analysis (PCA)
mapping shown in Figure 1A. Afterwards, the data were
normalized by global normalization with robust multichip
average (RMA) and detection above background (DABG)
using the Expression Console software (Affymetrix, Santa
Clara, CA, USA) (Figure 1B). The differentially expressed
miRNAs between patient and control groups of urine and
serum samples are shown in the form of a scatter plot
in Figures 2A and 2B. In order to better characterize the
differential miRNAs to distinguish between patient and
healthy control samples, the miRNAs were further used to
heat map clustering analysis and urine and serum sample
clusters shown in Figures 2C and 2D, respectively. The
mature human miRNAs represented on the microarray
showed that 103 (3.99%) miRNAs were expressed totally
in all groups (patient and healthy control groups from
urine and serum samples). There were 49 (1.9%) and
14 (0.54%) up- and downregulated urine miRNAs,
respectively, when the patient and healthy control groups
were compared (Table 2). There were 19 (0.73 21 (0.81%)
up- and downregulated serum miRNAs (Table 2), when
the patient and healthy control groups were compared.
Overlapping miRNAs in all groups of urine and serum
samples are summarized in Table 2. Two of the four miRNAs
demonstrated significant correlations between the urine
and serum samples. In this study, the MIR4532 (Gene
ID:100616353) and MIR4706 (Gene ID:100616490) were
upregulated in urine and downregulated in serum samples.
The MIR320A (Gene ID:407037) was downregulated in
both urine and serum samples (fold change –4.2 and –2.05
respectively); in addition, MIR6750 (Gene ID:102466192)
was upregulated in both urine and serum samples (fold
change +2.23 and +2.37, respectively). Moreover, to check
the accuracy of the microarray miRNA quantification, the
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Figure 1. A) Loading plot showing the components from Principal Component Analysis (PCA) of all probe sets from Affymetrix
GeneChip miRNA Arrays 4.0 hybridized. The observed four groups are shown (red cube: patient urine samples, blue cube: patient
serum, yellow cube: control urine and green cube: control serum). B) Pearson’s correlation of the signal obtained from Affymetrix
miRNA Arrays 4.0 GeneChip® hybridized.

two miRNAs (MIR320A and MIR6750) were reexamined
by using qRT-PCR in 76 samples (38 urine and 38 serum
samples from eight patients and 30 healthy controls). The
annealing temperatures were evaluated before qRT-PCR
reactions and the results were 56 °C for the reference gene
(RNU6-2), 58 °C for MIR320A, and 55 °C for MIR6750.
The selected candidate miRNAs in urine and serum
samples of eight patients were compared. The MIR320A
expression levels of the urine and serum samples of the

healthy controls were higher in serum samples (p =
0.0023), and a similar result was observed in patient
samples (p = 0.0026) (Figures 3A and 3B, respectively).
In addition, the MIR320A expression levels between the
patient and healthy control groups were compared, and
higher levels were observed in patients (p = 0.0168) (Figure
3C). However, these levels were not found to be significant
in serum samples (p > 0.05) (Figure 3D). The MIR6750
expression levels between urine and serum samples of
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Figure 2. A) Scatter plot from GeneChip miRNA Arrays 4.0 analysis. The expression profiles of urine samples comparing patient
and control groups were plotted. Significant spots in red and green represents the number of miRNAs in urine samples which are
upregulated and downregulated, respectively (Y axis shows expression levels in control urine samples, X axis shows expression levels in
patient urine samples. B) Scatter plot from GeneChip miRNA Arrays 4.0 analysis. The expression profiles of serum samples comparing
patient and control groups were plotted. Significant spots in red and green represents the number of miRNAs in serum samples which
are upregulated and downregulated, respectively (Y axis shows expression levels in control serum samples, X axis shows expression
levels in patient serum samples. C) Heat map from GeneChip miRNA Arrays 4.0 analysis of urine samples. The clustering of samples was
mainly divided into two major clusters; one was the control samples and the other was patient samples. Adjusted p-value threshold: 0.05.
Red represents the upregulated miRNA while green represents the downregulated miRNA respectively. D) Heat map from GeneChip
miRNA Arrays 4.0 analysis of serum samples. The clustering of samples was mainly divided into two major clusters; one was the control
samples and the other was patient samples. Adjusted p-value threshold: 0.05. Red represents the upregulated miRNA while green
represents the downregulated miRNA, respectively.

the healthy controls were not different (p > 0.05) (Figure
4A). The MIR6750 increased only in serum samples of the
patients when compared to urine specimens (p = 0.0079)
(Figure 4B). In addition, the comparisons of urine and
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serum samples between the control and patient groups
were not found to be significant (p > 0.05) (Figures 4C and
4D, respectively).
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Table 2. Transcript ID and fold change of miRNAs in urine and
serum specimens of patients and healthy groups. Overlapping
miRNAs both for serum and urine specimens are marked as
bold. –: downregulated, +: upregulated.
miR ID

Accession #

Specimens

MIR4532

MIMAT0019071 Urine/Serum +3.99/–2.05

MIR6750

MIMAT0027400 Urine/Serum +2.23/+2.37

MIR4706

MIMAT0019806 Urine/Serum +2.66/–2.72

MIR320A

MIMAT0000510 Urine/Serum –4.2/–2.05

MIR744

MIMAT0004945 Urine

+6.21

MIR6726

MIMAT0027353 Urine

+5.49

MIR4485

MIMAT0019019 Urine

+5.34

MIR6813

MIMAT0027526 Urine

+5.24

MIR3180–4

MIMAT0018178 Urine

+4.33

MIR3197

MIMAT0015082 Urine

+4.24

MIR4532

MIMAT0019071 Urine

+3.99

MIR4674

MI0017305

Urine

+3.57

MIR4449

MIMAT0018968 Urine

+3.52

MIR3180–1

MIMAT0015058 Urine

+3.39

MIR3663

MIMAT0018085 Urine

+3.14

MIR6824

MIMAT0027548 Urine

+3.01

MIR885

MIMAT0004948 Urine

+2.91

MIR4749

MIMAT0019885 Urine

+2.9

MIR6819

MIMAT0027538 Urine

+2.84

MIR6798

MIMAT0027496 Urine

+2.74

MIR4706

MIMAT0019806 Urine

+2.66

MIR3178

MIMAT0015055 Urine

+2.6

MIR6075

MIMAT0023700 Urine

+2.57

MIR3937

MIMAT0018352 Urine

+2.47

MIR1275

MIMAT0005929 Urine

+2.42

MIR423

MIMAT0004748 Urine

+2.4

MIR6787

MIMAT0027474 Urine

+2.4

MIR6845

MIMAT0027590 Urine

+2.39

MIR4649

MIMAT0019711 Urine

+2.38

MIR6782

MIMAT0027464 Urine

+2.37

MIR3648–1

MI0016048

Urine

+2.36

MIR4674

MIMAT0019756 Urine

+2.32

MIR4758

MI0017399

+2.31

MIR6808

MIMAT0027516 Urine

+2.3

MIR6090

MI0020367

+2.3

MIR1909

MIMAT0007883 Urine

+2.29

MIR6848

MIMAT0027596 Urine

+2.29

MIR378H

MIMAT0018984 Urine

+2.27

MIR6802

MIMAT0027504 Urine

+2.24

MIR6750

MIMAT0027400 Urine

+2.23

Urine
Urine

Fold Change

miR ID

Accession #

Specimens

Fold Change

MIR4466

MI0016817

Urine

+2.23

MIR6510

MIMAT0025476 Urine

+2.21

MIR6778

MIMAT0027456 Urine

+2.2

MIR4750

MIMAT0019887 Urine

+2.16

MIR4673

MIMAT0019755 Urine

+2.15

MIR7150

MIMAT0028211 Urine

+2.14

MIR1224

MIMAT0005458 Urine

+2.13

MIR4467

MIMAT0018994 Urine

+2.09

MIR7110

MIMAT0028117 Urine

+2.09

MIR320E

MI0014234

Urine

+2.08

MIR4417

MIMAT0018929 Urine

+2.05

MIR4274

MIMAT0016906 Urine

+2.02

MIR4492

MIMAT0019027 Urine

+2.02

MIR4701

MIMAT0019799 Urine

–2.08

MIR6812

MIMAT0027524 Urine

–2.12

MIR6124

MIMAT0024597 Urine

–2.13

MIR3613

MIMAT0017990 Urine

–2.15

MIR4440

MIMAT0018958 Urine

–2.16

MIR575

MIMAT0003240 Urine

–2.28

MIR6840

MIMAT0027583 Urine

–2.31

MIR6716

MIMAT0025845 Urine

–2.52

MIR8071–1

MIMAT0030998 Urine

–2.76

MIR320C1

MIMAT0005793 Urine

–2.99

MIR320D1

MIMAT0006764 Urine

–3.19

MIR6790

MIMAT0027480 Urine

–3.58

MIR3188

MIMAT0015070 Urine

–3.63

MIR320A

MIMAT0000510 Urine

–4.2

MIR486–1

MIMAT0002177 Serum

+11.02

MIR149

MIMAT0004609 Serum

+5.57

MIR1237

MIMAT0022946 Serum

+4.94

MIR4687

MIMAT0019775 Serum

+4.84

MIR4463

MIMAT0018987 Serum

+4.38

MIR4529

MIMAT0019068 Serum

+3.93

MIR4508

MIMAT0019045 Serum

+3.28

MIR4763

MIMAT0019913 Serum

+3.15

MIR7706

MI0025242

+2.82

MIR6756

MIMAT0027412 Serum

+2.8

MIR6776

MI0022621

Serum

+2.72

MIR6715A

MIMAT0025841 Serum

+2.55

MIR6869

MIMAT0027638 Serum

+2.55

MIR3196

MIMAT0015080 Serum

+2.48

MIR409

MIMAT0001639 Serum

+2.43

MIR6750

MIMAT0027400 Serum

+2.37

Serum
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miR ID

Accession #

Specimens

MIR4728

MIMAT0019849 Serum

+2.13

MIR4700

MIMAT0019797 Serum

+2.09

MIR6819

MIMAT0027539 Serum

+2.06

MIR6803

MIMAT0027506 Serum

– 2.01

MIR4785

MIMAT0019949 Serum

–2.03

MIR320A

MIMAT0000510 Serum

–2.05

MIR4532

MIMAT0019071 Serum

–2.05

MIR4490

MI0016852

–2.06

MIR1180

MIMAT0026735 Serum

–2.08

MIR3613

MIMAT0017991 Serum

– 2.09

MIR6850

MIMAT0027600 Serum

–2.22

MIR6780B

MIMAT0027572 Serum

–2.28

MIR4668

MIMAT0019745 Serum

–2.45

MIR1908

MIMAT0007881 Serum

–2.48

MIR1228

MIMAT0005582 Serum

–2.52

MIR940

MIMAT0004983 Serum

–2.65

MIR4706

MIMAT0019806 Serum

–2.72

MIR668

MIMAT0026636 Serum

–2.95

MIR602

MIMAT0003270 Serum

–3.00

MIR4497

MIMAT0019032 Serum

–3.19

MIR4707

MIMAT0019807 Serum

–3.96

MIR6511B1

MIMAT0025847 Serum

–5.07

MIR6126

MIMAT0024599 Serum

–18.39

MIR4484

MIMAT0019018 Serum

–23.97

Serum

Fold Change

4. Discussion
miRNAs play an important role in the regulation of
gene expression through direct binding to the mRNA of
protein-encoding genes and affect posttranscriptional
suppression of its target genes. Besides, there are several
miRNAs which have a role in androgen independence in
PC [25,26].
Due to the low specificity of current diagnosis criteria,
investigations for higher specificity in PC diagnosis
still continue while there is a gap for urinary biomarker
tests particularly for urologic diseases. Importantly, the
observed aberrant miRNA expression in PC patients could
be either disease-specific or present in all patients with
other urinary diseases [27].
In the present study, we recruited patients with
newly diagnosed PC who had not had any treatment yet.
Then, we analyzed the entire urinary and serum miRNA
expression profiles and compared them with healthy
controls. Afterwards, the overlapped and correlated
miRNAs were further evaluated by qRT-PCR. The
microarray expression data showed that 49 miRNAs
were upregulated in urinary samples of PC patients, and
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14 miRNAs were downregulated. In addition, up- and
downregulated serum samples contain 19 and 21 miRNAs,
respectively, when compared with healthy controls as
well. The overlapping miRNAs are MIR4532, MIR4706,
MIR320A, and MIR6750 between urine and serum
samples which were detected for both patients and healthy
controls. However, the microarray results were not found
to be completely consistent. According to the overlapping
miRNAs between patient and control groups, only two
miRNAs (MIR4532 and MIR4706) were upregulated
in urine although they were downregulated in serum
samples, which may be due to the different samples being
pooled for microarray analysis and/or the possible effects
of different ages of the subjects and varying pathological
cancer grades of patients. The MIR4532 is listed as having
possible oncogene regulatory properties which have
not been investigated specifically [28]. Only one report
demonstrated that MIR4532 was found in malignant B cells
[29]. However, this miRNA was withdrawn by miRBase,
and NCBI reported that the record was discontinued on
14-Mar-2018. On the other hand, MIR4706 was identified
in breast tissue [30], and there were no data for functional
properties for this miRNA yet.
Interestingly, the MIR320A was downregulated for
both urine and serum samples in microarray expression
analysis. On the contrary, urine samples of the patient
group showed a significant increase in the expression of
MIR320A when compared to the control group by qRTPCR. This result is also consistent with that of a previous
study by Porkka et al., which showed upregulation of
MIR320A in prostate carcinomas when compared to
BPH specimens [31]. In addition, Ristou et al. found nine
different miRNAs in plasma samples of colorectal cancer
patients where MIR320A level was upregulated before
surgery, and decreased expression was recorded after
surgery [32]. Moreover, Okato et al. reported a significant
decrease in the expression of MIR320A in PC tissue
when compared to normal prostate tissue. Furthermore,
a previous study proved that cell proliferation, cell
migration, and cell invasion are significantly inhibited in
the PC cell line by silencing lysosomal-associated protein
1 (LAMP1), which is the target of MIR320A; consequently,
the data suggested that MIR320A may function as a
tumor suppressor [33]. It has been recently observed that
MIR320A suppresses tumor cell proliferation and invasion
of renal cancer cells by targeting forkhead box protein M1
(FoxM1) [34].
We also analyzed by microarray and verified by qRTPCR the expression levels of MIR6750 in serum and urine
samples which were not found to be significant between
the patient and control group. In one report, MIR6750 was
listed as human splicing-derived miRNAs (“mirtrons”)
[35]. Currently, this is the only data about MIR6750 and
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Figure 3. MIR320A expression results. A) Urine and serum sample expression levels of the control group (p = 0.0023). B) Urine and
serum sample expression levels of the patient group (p = 0.0026). C) Urine sample expression levels of the control and patient group (p
= 0.0168). D) Serum sample expression levels of the control and patient group (p = 0.0826).

its relation with PC which was found in both urine and
serum samples. However, apart from prostate cancer,
only one study in nonsmall cell lung cancer found 59
downregulated miRNAs by silencing the insulin-like
growth factor 1 receptor (IGF-1R) gene, and MIR6750 has
been shown to be downregulated [36].
The limitations of our study are that we did not
evaluate the cellular sources of miRNAs. Particularly
urine specimens have podocytes, inflammatory cells, renal
tubular, and urinary tract epithelial cells. In addition,
urine samples possibly did not include exosomes which
are the major sources of miRNAs in body fluids. Moreover,
the low g value of centrifugation process also explains the
low concentrations of total RNAs from urinary samples.
Therefore, the underlying outcome of the changes
and correlations observed in this study needs further
investigation with more patient samples.

5. Conclusion
There are conflicting results in numerous studies of
miRNA expression patterns in prostate cancer. In sum,
several studies reported that miRNAs are downregulated
in tumors, whereas others reported them to be upregulated
[6]. The complexity of miRNAs is not fully clarified either
in cancer development or PC in general.
In conclusion, the microarray expression data provided
valuable results for possible noninvasive biomarkers for PC
patients. Particularly the expression profile of MIR320A
was significantly altered in urine specimens of the PC
patients. Further studies with large cohorts that include
both patients and healthy controls are needed to validate
the expression profiles of overlapping miRNAs.
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Figure 4. MIR6750 expression results. A) Urine and serum sample expression levels of the control group (p > 0.05). B) Urine and serum
sample expression levels of the patient group (p = 0.0079). C. Urine sample expression levels of the control and patient group (p > 0.05).
D. Serum sample expression levels of the control and patient group (p > 0.05).
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